ArticleFrontiers in endocrinology2025
hs-CRP/HDL-C can predict the risk of all cause mortality in cardiovascular-kidney-metabolic syndrome stage 1-4 patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inflammation as a Prognostic Marker in Cardiovascular Kidney Metabolic Syndrome: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- hs-CRP/HDL Ratio Across Obesity and Type 2 Diabetes Mellitus Phenotypes in Adults: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
- Association of C-reactive protein/high-density lipoprotein cholesterol ratio with stroke in Chinese adults across different glycemic status.Lipids in health and disease · 2026Article
- The Associations of Anthropometric Indices With Stages and Mortality in Cardiovascular-Kidney-Metabolic Syndrome: Insights From NHANES.Reviews in cardiovascular medicine · 2026Article
- Association of High-Sensitivity C-Reactive Protein with Metabolic Syndrome and Transitions in Metabolic Status: A Combined Cross-Sectional and Cohort Study with Gender Differences in Chinese Adults.Journal of inflammation research · 2026Article
- Residual cholesterol inflammatory index and its prognostic role in mortality among individuals with cardiovascular-kidney-metabolic syndrome stages 0-3 based on U.S. and Chinese national cohorts.European journal of medical research · 2025Article
- Using the American heart association's new 'cardiovascular-kidney-metabolic syndrome' metrics to assess life expectancy in us adults: A life table analysis.American journal of preventive cardiology · 2025Article
- Association of estimated glucose disposition rate with aging acceleration and mortality risk in individuals with cardiovascular-kidney-metabolic syndrome: evidence from two large national population-based studies.Cardiovascular diabetology · 2025Article
- C-reactive protein-triglyceride glucose index predicts mortality in cardiovascular-kidney-metabolic syndrome stage 0-3: a prospective cohort study.Diabetology & metabolic syndrome · 2025Article
- Association between hs-CRP/HDL-C ratio and risk of prediabetes or diabetes: a cross-sectional study based on NHANES 2015-2023.BMC endocrine disorders · 2025Article
- Association between the cardiometabolic index and cardiovascular disease risk in patients with cardiovascular-kidney-metabolic syndrome: a cohort study.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The precise function of the hs-CRP/HDL-C ratio in forecasting the long-term mortality risk of patients with stages 1-4 of Cardiovascular-Kidney-Metabolic (CKM) syndrome remains inadequately delineated. This study investigates the potential correlation between the hs-CRP/HDL-C ratio and long-term mortality risk in individuals with CKM syndrome stages 1-4. Methods: This prospective cohort study utilises data from the China Health and Retirement Longitudinal Study (CHARLS) project, encompassing 6,719 people who satisfied stringent criteria. We developed three Cox proportional hazards regression models to investigate the potential relationship between the hs-CRP/HDL-C ratio and long-term mortality risk in patients with CKM stages 1-4. We employed Restricted Cubic Spline (RCS) curves for analysis to identify any potential nonlinear correlations. Furthermore, we performed Receiver Operating Characteristic (ROC) curve analysis to evaluate predictive performance and identify the appropriate cut-off value. To enhance the research findings, we conducted a stratified analysis to investigate the influence of various sociodemographic factors on this association. Results: In individuals with CKM syndrome stages 1-4, the 10-year incidence of all-cause mortality was 14.1%. Upon controlling for additional potential confounding variables, the outcomes of the Cox proportional hazards regression model distinctly demonstrated a statistically significant linear positive association between the hs-CRP/HDL-C ratio and the long-term mortality risk in patients. For each quartile increase in the hs-CRP/HDL-C ratio, the probability of poor outcomes (i.e., mortality) escalated by 15% (Hazard Ratio, HR = 1.15, 95% Confidence Interval, CI: 1.09-1.22, p-value < 0.001). Moreover, the integration of the hs-CRP/HDL-C ratio into the baseline risk prediction model, with all pertinent factors thoroughly adjusted, markedly enhanced the model's predictive capacity, facilitating a more precise assessment of long-term mortality risk in patients with CKM syndrome stages 1-4. Conclusion: This study identified a positive linear association between the hs-CRP/HDL-C ratio and long-term mortality risk in patients with stages 1 to 4 of CKM syndrome. This remarkable discovery not only offers a crucial reference for enhancing early individualised treatment options but also greatly aids in the early identification of patients with poor prognoses, hence presenting a novel perspective for improving clinical management pathways for these individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.